Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) have earned an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.67.

IPHA has been the topic of several recent analyst reports. UBS Group restated a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. HC Wainwright reiterated a “buy” rating on shares of Innate Pharma in a research note on Monday, September 21st. Citigroup upgraded Innate Pharma from a “buy” rating to an “outperform” rating in a report on Tuesday, August 11th. Leerink Partners raised Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a research report on Tuesday, August 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Innate Pharma in a research note on Tuesday, September 22nd.

Innate Pharma Stock Performance

Shares of IPHA stock opened at $1.56 on Wednesday. The company has a fifty day moving average price of $1.96 and a two-hundred day moving average price of $1.75. Innate Pharma has a one year low of $1.17 and a one year high of $2.71.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune cells that can recognize and attack tumors. Its product candidates include monoclonal antibodies, immune-cell engagers and other treatments designed to stimulate or direct immune responses against cancer.

Innate Pharma’s pipeline has included lacutamab, an antibody targeting KIR3DL2 for the treatment of certain T-cell lymphomas, including cutaneous T-cell lymphoma.